Optimizing ATR inhibition and Cisplatin Synergy in Ewing Sarcoma
EWSR1::FLI1-mediated dysregulation of cellular machinery opens up potential new avenues for Ewing sarcoma treatment. A recent study demonstrates that pharmacologic ATR kinase inhibition dramatically synergizes with low-dose cisplatin through EWSR1::FLI1-dependent rewiring of transcription, DNA repai...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
15 August 2024
|
| In: |
Clinical cancer research
Year: 2024, Volume: 30, Issue: 16, Pages: 3358-3360 |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-24-1047 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1158/1078-0432.CCR-24-1047
|
| Author Notes: | Shunya Ohmura and Thomas G.P. Grünewald |
| Summary: | EWSR1::FLI1-mediated dysregulation of cellular machinery opens up potential new avenues for Ewing sarcoma treatment. A recent study demonstrates that pharmacologic ATR kinase inhibition dramatically synergizes with low-dose cisplatin through EWSR1::FLI1-dependent rewiring of transcription, DNA repair, and translation machinery, which could maximize the therapeutic window of the combinatory therapy. |
|---|---|
| Item Description: | Gesehen am 09.10.2024 |
| Physical Description: | Online Resource |
| ISSN: | 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-24-1047 |